Literature DB >> 19161298

Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction.

Jonathon N Bauman1, Joan M Kelly, Sakambari Tripathy, Sabrina X Zhao, Wing W Lam, Amit S Kalgutkar, R Scott Obach.   

Abstract

In vitro covalent binding studies in which xenobiotics are shown to undergo metabolism-dependent covalent binding to macromolecules have been commonly used to shed light on the biochemical mechanisms of xenobiotic-induced toxicity. In this paper, 18 drugs (nine hepatotoxins and nine nonhepatotoxins) were tested for their proclivity to demonstrate metabolism-dependent covalent binding to macromolecules in human liver S-9 fraction (9000 g supernatant) or human hepatocytes, as an extension to previous work that used human liver microsomes published in this journal [ Obach et al. ( 2008 ) Chem. Res. Toxicol. 21 , 1814 -1822 ]. In the S-9 fraction, seven out of the nine drugs in each category demonstrated some level of metabolism-dependent covalent binding. Inclusion of reduced glutathione, cofactors needed by conjugating enzymes, and other parameters (total daily dose and fraction of total intrinsic clearance comprised by covalent binding) improved the ability of the system to separate hepatotoxins from nonhepatotoxins to a limited extent. Covalent binding in human hepatocytes showed that six out of the nine hepatotoxins and four out of eight nonhepatotoxins demonstrated covalent binding. Taking into account estimates of total daily body burden of covalent binding from the hepatocyte data showed an improvement over other in vitro systems for distinguishing hepatotoxins from nonhepatotoxins; however, this metabolism system still displayed some false positives. Combined with the previous study using liver microsomes, these findings identify the limitations of in vitro covalent binding data for prospective prediction of hepatotoxicity for new drug candidates and highlight the need for a better understanding of the link between drug bioactivation, covalent adduct formation, and toxicity outcomes. Directly relating covalent binding to hepatotoxicity is likely an oversimplification of the process whereby adduct formation ultimately leads to toxicity. Understanding underlying complexities (e.g., which macromolecules are important covalent binding targets, interindividual differences in susceptibility, etc.) will be essential to any understanding of the problem of metabolism-dependent hepatotoxicity and predicting toxicity from in vitro experiments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19161298     DOI: 10.1021/tx800407w

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  16 in total

Review 1.  Mechanisms of drug toxicity and relevance to pharmaceutical development.

Authors:  F Peter Guengerich
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

Review 2.  Managing the challenge of chemically reactive metabolites in drug development.

Authors:  B Kevin Park; Alan Boobis; Stephen Clarke; Chris E P Goldring; David Jones; J Gerry Kenna; Craig Lambert; Hugh G Laverty; Dean J Naisbitt; Sidney Nelson; Deborah A Nicoll-Griffith; R Scott Obach; Philip Routledge; Dennis A Smith; Donald J Tweedie; Nico Vermeulen; Dominic P Williams; Ian D Wilson; Thomas A Baillie
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

3.  Practical application of the interim internal threshold of toxicological concern (iTTC): a case study based on clinical data.

Authors:  Abdulkarim Najjar; Corie A Ellison; Sebastien Gregoire; Nicola J Hewitt
Journal:  Arch Toxicol       Date:  2022-09-23       Impact factor: 6.168

Review 4.  Idiosyncratic Drug Reactions: A 35-Year Chemical Research in Toxicology Perspective.

Authors:  Jack Uetrecht
Journal:  Chem Res Toxicol       Date:  2022-06-10       Impact factor: 3.973

5.  Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes.

Authors:  Mark P Grillo; Jill C M Wait; Michelle Tadano Lohr; Smriti Khera; Leslie Z Benet
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

6.  Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries.

Authors:  Abhishek Srivastava; Lu-Yun Lian; James L Maggs; Masautso Chaponda; Munir Pirmohamed; Dominic P Williams; B Kevin Park
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

7.  Modeling the Bioactivation and Subsequent Reactivity of Drugs.

Authors:  Tyler B Hughes; Noah Flynn; Na Le Dang; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2021-01-26       Impact factor: 3.739

Review 8.  Deleterious effects of reactive metabolites.

Authors:  Sabry M Attia
Journal:  Oxid Med Cell Longev       Date:  2010 Jul-Aug       Impact factor: 6.543

9.  Case Study 11: Considerations for Enzyme Mapping Experiments-Interaction Between the Aldehyde Oxidase Inhibitor Hydralazine and Glutathione.

Authors:  Rachel D Crouch; Jessica L Beers; Klarissa D Jackson
Journal:  Methods Mol Biol       Date:  2021

10.  Alkylation damage by lipid electrophiles targets functional protein systems.

Authors:  Simona G Codreanu; Jody C Ullery; Jing Zhu; Keri A Tallman; William N Beavers; Ned A Porter; Lawrence J Marnett; Bing Zhang; Daniel C Liebler
Journal:  Mol Cell Proteomics       Date:  2014-01-15       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.